Back to Awarded Treatment Trials
Awarded Trial: 06TGF-966
Secondary Drug Intervention
Duration of Study Period for Each Subject
BPRS, Biomakers, SDS, SANS, Quality of Life, MCCB
Sixty-nine (69) patients with schizophrenia, both smokers and nonsmokers, were randomized to varenicline or placebo as adjunct medication for 8 weeks. Varenicline has activity on the nicotine acetylcholine receptors. Those on varenicline had significantly reduced P-50 sensory gating and startle reactivity and improved executive function. There was also a trend toward improved symptoms but no improvement in other cognitive functions.
Hong EL, Thaker GK, McMahon RP. Effects of Moderate-Dose Treatment with Varenicline on Neurobiological and Cognitive Biomarkers in Smokers and Nonsmokers With Schizophrenia or Schizoaffective Disorder. Arch Gen Psychiatry Dec. 2011; 68(12):1195-1206.
Maryland Psychiatric Research Centrer
University of Maryland School of Medicine
PO Box 21247
City or Town
State or Province
Zip or Postal Code